Literature DB >> 35237107

Transanal Local Excision of Rectal Cancer after Neoadjuvant Chemoradiation: Is There a Place for It or Should Be Avoided at All Costs?

Rodrigo Oliva Perez1,2, Guilherme Pagin São Julião1,2, Bruna Borba Vailati1,2.   

Abstract

Tumor response to neoadjuvant chemoradiation (nCRT) with tumor downsizing and downstaging has significantly impacted the number of patients considered to be appropriate candidates for transanal local excision (TLE). Some patients may harbor small residual lesions, restricted to the bowel wall. These patients, who exhibit major response ("near-complete") by digital rectal examination, endoscopic assessment, and radiological assessment may be considered for this approach. Although TLE is associated with minimal postoperative morbidity, a few clinical consequences and oncological outcomes must be evaluated in advance and with caution. In the setting of nCRT, a higher risk for clinically relevant wound dehiscences leading to a considerable risk for readmission for pain management has been observed. Worse anorectal function (still better than after total mesorectal excision [TME]), worsening in the quality of TME specimen, and higher rates of abdominal resections (in cases requiring completion TME) have been reported. The exuberant scar observed in the area of TLE also represents a challenging finding during follow-up of these patients. Local excision should be probably restricted for patients with primary tumors located at or below the level of the anorectal ring (magnetic resonance defined). These patients are otherwise candidates for abdominal perineal resections or ultra-low anterior resections with coloanal anastomosis frequently requiring definitive stomas or considerably poor anorectal function. Thieme. All rights reserved.

Entities:  

Keywords:  local excision; neoadjuvant chemoradiation; organ preservation arm; rectal cancer

Year:  2022        PMID: 35237107      PMCID: PMC8885162          DOI: 10.1055/s-0041-1742112

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  47 in total

1.  Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control.

Authors:  Iris D Nagtegaal; Cornelis J H van de Velde; Erik van der Worp; Ellen Kapiteijn; Phil Quirke; J Han J M van Krieken
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

2.  Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations.

Authors:  Angelita Habr-Gama; Rodrigo Oliva Perez; Desidério Roberto Kiss; Viviane Rawet; Arceu Scanavini; Pedro Marcos Santinho; Wladimir Nadalin
Journal:  Hepatogastroenterology       Date:  2004 Nov-Dec

Review 3.  Risk of lymph node metastasis in T1 carcinoma of the colon and rectum.

Authors:  Riccardo Nascimbeni; Lawrence J Burgart; Santhat Nivatvongs; Dirk R Larson
Journal:  Dis Colon Rectum       Date:  2002-02       Impact factor: 4.585

Review 4.  Local Excision Techniques for Rectal Cancer After Neoadjuvant Chemoradiotherapy: What Are We Doing?

Authors:  Fraser McLean Smith; Abdul Ahad; Rodrigo Oliva Perez; John Marks; Krzysztof Bujko; Richard J Heald
Journal:  Dis Colon Rectum       Date:  2017-02       Impact factor: 4.585

5.  Magnetic resonance imaging following neoadjuvant chemoradiation and transanal endoscopic microsurgery for rectal cancer.

Authors:  G P São Julião; C D Ortega; B B Vailati; A Habr-Gama; L M Fernandez; J Gama-Rodrigues; S E Araujo; R O Perez
Journal:  Colorectal Dis       Date:  2017-06       Impact factor: 3.788

6.  Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.

Authors:  Jacob A Greenberg; David Shibata; James E Herndon; Glenn D Steele; Robert Mayer; Ronald Bleday
Journal:  Dis Colon Rectum       Date:  2008-06-07       Impact factor: 4.585

7.  Transanal endoscopic microsurgery for the treatment of rectal cancer: comparison of wound complication rates with and without neoadjuvant radiation therapy.

Authors:  John H Marks; E B Valsdottir; A DeNittis; S S Yarandi; D A Newman; I Nweze; M Mohiuddin; G J Marks
Journal:  Surg Endosc       Date:  2009-03-05       Impact factor: 4.584

8.  Local excision of rectal cancer followed by radical surgery because of poor prognostic features does not compromise the long term oncologic outcome.

Authors:  G Gagliardi; T R Newton; H R Bailey
Journal:  Colorectal Dis       Date:  2013-11       Impact factor: 3.788

9.  Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial.

Authors:  Cécile Ortholan; Pascale Romestaing; Olivier Chapet; Jean Pierre Gerard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-01       Impact factor: 7.038

10.  Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.

Authors:  Julio Garcia-Aguilar; Lindsay A Renfro; Oliver S Chow; Qian Shi; Xiomara W Carrero; Patricio B Lynn; Charles R Thomas; Emily Chan; Peter A Cataldo; Jorge E Marcet; David S Medich; Craig S Johnson; Samuel C Oommen; Bruce G Wolff; Alessio Pigazzi; Shane M McNevin; Roger K Pons; Ronald Bleday
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

View more
  2 in total

1.  Role of Local Excision for Suspected Regrowth in a Watch and Wait Strategy for Rectal Cancer.

Authors:  Barbara M Geubels; Vincent M Meyer; Henderik L van Westreenen; Geerard L Beets; Brechtje A Grotenhuis
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  Association between microsatellite instability and tumor response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Soo Young Lee; Duck-Woo Kim; Jaram Lee; Hyeong-Min Park; Chang Hyun Kim; Kyung-Hwa Lee; Heung-Kwon Oh; Sung-Bum Kang; Hyeong Rok Kim
Journal:  Ann Surg Treat Res       Date:  2022-09-06       Impact factor: 1.766

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.